[Laboratory and clinical studies on cefminox].
Laboratory and clinical studies were performed on cefminox (CMNX, MT-141), a new cephamycin antibiotic, and results were as follows. Antimicrobial activities. MICs of CMNX against various clinical isolates were determined with the inoculum size of 10(6) cells/ml. Percentages of strains susceptible to 12.5 micrograms/ml or less were 4% for S. aureus, 0% for E. faecalis, 100% for E. coli, 81% for K. pneumoniae, 3% for Enterobacter sp., 18% for S. marcescens, 90% for P. mirabilis, 88% for indole-positive Proteus sp. 100% for S. flexneri, 100% for Salmonella sp., 0% for Citrobacter sp. and 0% for P. aeruginosa. Most of those sensitive strains were inhibited by 0.39-0.78 microgram/ml. These activities were better than those of cefmetazole and cefazolin, but were not as good as those of cefoperazone. Clinical efficacy Three patients with pneumonia, 1 with pneumonia and sepsis, and 1 with urinary tract infection were treated with CMNX daily dose of 1-4 g for 7-31 days. Clinical responses were excellent in 1, good in 3, poor in 2 patients (contained a double case). Bacteriological effects were good for E. coli, K. pneumoniae and S. liquefaciens, poor for P. aeruginosa and P. mirabilis. C. freundii, A. calcoaceticus and E. faecalis were cultured after treatment. No side effect and no abnormal change of laboratory findings were seen in our cases.
D000368:Aged; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D002513:Cephamycins / Q000494:pharmacology / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006801:Humans; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008297:Male; D011014:Pneumonia / Q000188:drug therapy*; D011513:Proteus mirabilis / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D018805:Sepsis / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002513:Cephamycins; C046079:cefminox